论文部分内容阅读
目的:探讨β抑制蛋白质-1(β-arrestin1)在系统性红斑狼疮(SLE)患者血清中的水平及其与疾病活动性的关系。方法:收集临床确诊的31例SLE患者及31例健康体检者的血清。根据SLEDAI评分≥10或<10,将31例SLE患者分为活动期和缓解期,ELISA测定健康对照与31例SLE患者血清中β抑制蛋白质-1(β-arrestin1)的水平,并采用SPSS13.0软件对各组数据进行差异性比较和相关分析。结果:SLE患者血清中β-arrestin1的水平(0.252μg/L)低于健康人(0.501μg/L),具有统计学意义(P<0.05);SLE活动期(SLEDAI评分≥10)患者血清中β-arrestin1水平(0.133μg/L)低于缓解期(SLEDAI评分<10)(0.342μg/L),亦具有统计学意义(P<0.01);抗核抗体滴度1∶80 SLE患者血清中β-ar-restin1的水平低于抗核抗体1∶40,(0.214μg/Lvs0383μg/L,P<0.05)。结论:血清β-arrestin1水平在SLE患者中明显降低,且与疾病的活动性呈一定程度负相关。
Objective: To investigate the serum level of β-arrestin1 in patients with systemic lupus erythematosus (SLE) and its relationship with disease activity. Methods: Sera from 31 SLE patients and 31 healthy subjects were collected. According to SLEDAI score≥10 or <10, 31 patients with SLE were divided into active phase and remission phase. Serum levels of β-arrestin1 in healthy controls and 31 SLE patients were measured by ELISA and SPSS13 was used. 0 software for each group of data for comparison and correlation analysis. Results: The level of β-arrestin1 in serum of SLE patients was lower than that of healthy people (0.501 μg / L, 0.252 μg / L, P <0.05) β-arrestin1 level (0.133μg / L) was lower than the remission stage (SLEDAI score <10) (0.342μg / L), also with statistical significance (P <0.01) The level of β-ar-restin1 was lower than the antinuclear antibody 1:40 (0.214 μg / L vs0383 μg / L, P <0.05). Conclusion: Serum β-arrestin1 level is significantly lower in patients with SLE, and has a certain degree of negative correlation with the activity of the disease.